Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

The oncologist - 1 May 2016

Soverini Simona, De Benedittis Caterina, Mancini Manuela, Martinelli Giovanni

Abstract excerpt

UNLABELLED: : Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients requires integration of clinical and laboratory monitoring. Assessment of molecular response (MR) by real-time quantitative polymerase chain reaction is the most sensitive way to monitor tyrosine kinase inhibitor (TKI) treatment efficacy. Besides major molecular response, which has emerged as a safe haven for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to ABL1 gene
Share to BCR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 27032870
DOI: 10.1634/theoncologist.2015-0337
PMCID: PMC4861357

Genes

ABL1
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.PMID 27032870Read ↗

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].Semantic proximity Read ↗

Present and future of molecular monitoring in chronic myeloid leukaemia.Semantic proximity Read ↗

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read ↗

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read ↗

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.Semantic proximity Read ↗

Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.Semantic proximity Read ↗

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read ↗

Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.Semantic proximity Read ↗

Practical considerations for monitoring patients with chronic myeloid leukemia.Semantic proximity Read ↗

Measurable residual disease in chronic myeloid leukemiaSemantic proximity Read ↗

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic ApproachesSemantic proximity Read ↗

Chronic myeloid leukemia: molecular monitoring in clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.